← Leaderboards
Gregory Paul Downey
National Jewish Health
$7,242,854
Attributed
$13,161,952
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,161,952 · 7
By mechanism
R01$6,555,391 · 3
UH3$5,007,305 · 1
UG3$853,963 · 1
R21$435,875 · 1
R41$309,418 · 1
Top collaborators
- Naftali Kaminski5 shared
- Derek C Radisky4 shared
- Evette S Radisky4 shared
- Maria L Padilla3 shared
- Joel Thomas Dudley2 shared
- James Cardelli1 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Carl W White$29,966,481
- Peter M Henson$23,575,855
- Elizabeth Frances Redente$4,940,326
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroFibroblastsLungProductionResponseExtracellular MatrixInjuryTissuesBleomycinSignal PathwayFibrosisPulmonary FibrosisPathway InteractionsDesignStructure Of Parenchyma Of LungCollagenMolecularBasePathogenesisMediator Of Activation ProteinPhosphorylationCicatrixAnimal ModelAttenuated
Grant awards (21)
Proteolysis in the Pathogenesis of ARDS$683,217
R01 · FY2025 · HL · contact PI
Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis$309,418
R41 · FY2025 · HL
Proteolysis in the Pathogenesis of ARDS$677,606
R01 · FY2024 · HL · contact PI
Proteolysis in the Pathogenesis of ARDS$696,074
R01 · FY2023 · HL · contact PI
Proteolysis in the Pathogenesis of ARDS$728,418
R01 · FY2022 · HL · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,511,058
UH3 · FY2021 · TR · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,726,316
UH3 · FY2020 · TR · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,672,515
UH3 · FY2019 · TR · contact PI
Checkpoint Function of PTPalpha in Pathological Fibrogenesis in the Lung$495,899
R01 · FY2019 · HL · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$97,416
UH3 · FY2019 · TR · contact PI
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$853,963
UG3 · FY2018 · TR · contact PI
Checkpoint Function of PTPalpha in Pathological Fibrogenesis in the Lung$495,899
R01 · FY2018 · HL · contact PI
Checkpoint Function of PTPalpha in Pathological Fibrogenesis in the Lung$498,875
R01 · FY2017 · HL · contact PI
Checkpoint Function of PTPalpha in Pathological Fibrogenesis in the Lung$522,172
R01 · FY2016 · HL · contact PI
Targeting PTPalpha to Prevent Lung Fibrosis$198,125
R21 · FY2015 · ES · contact PI
Targeting PTPalpha to Prevent Lung Fibrosis$237,750
R21 · FY2014 · ES · contact PI
Focal Adhesion Modulation of IL-1 Signaling: Importance in Pulmonary Fibrosis$390,000
R01 · FY2011 · HL · contact PI
Focal Adhesion Modulation of IL-1 Signaling: Importance in Pulmonary Fibrosis$390,000
R01 · FY2010 · HL · contact PI
Focal Adhesion Modulation of IL-1 Signaling: Importance in Pulmonary Fibrosis$390,000
R01 · FY2009 · HL · contact PI
Focal Adhesion Modulation of IL-1 Signaling: Importance in Pulmonary Fibrosis$197,231
R01 · FY2009 · HL · contact PI
Focal Adhesion Modulation of IL-1 Signaling: Importance in Pulmonary Fibrosis$390,000
R01 · FY2008 · HL · contact PI